Gary A. Lyons

Companies

• Travere Therapeutics, Inc.Board member Oct 10, 2014 to now¹
• Neurocrine BiosciencesBoard member Jan 23, 2006 to now²
• RIGEL PHARMACEUTICALS INCBoard member May 31, 2006 to Jul 12, 2023³
• Eledon Pharmaceuticals, Inc.Board member May 11, 2017 to May 2, 2023⁴
• Fresh Tracks Therapeutics, Inc.Board member May 19, 2006 to May 17, 2022⁵
• Plus TherapeuticsBoard member Oct 9, 2013 to Feb 9, 2018⁶
• HUMANIGEN, INCBoard member Aug 10, 2012 to Jul 14, 2015⁷
• Neurocrine BiosciencesChief executive officer Jan 23, 2006 to Oct 26, 2007²
• Neurocrine BiosciencesPresident Jan 23, 2006 to Oct 26, 2007²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Neurocrine Biosciences NBIX122,141 shares⁸$16.7M at $136.95May 21, 2026
• RPRIGEL PHARMACEUTICALS INC RIGL75,000 shares⁹$3.5M at $47.25May 26, 2023
• TTTravere Therapeutics, Inc. TVTX61,500 shares¹⁰$3.3M at $53.15Aug 18, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Aug 18, 2026Sold 900 shares at $63.86 of Travere Therapeutics, Inc.¹⁰
• Aug 18, 2026Sold 4,100 shares at $63.27 of Travere Therapeutics, Inc.¹⁰
• Aug 18, 2026Exercised options 5,000 shares at $17.44 of Travere Therapeutics, Inc.¹⁰
• Aug 17, 2026Sold 500 shares at $64.16 of Travere Therapeutics, Inc.¹⁰
• Aug 17, 2026Sold 2,600 shares at $63.50 of Travere Therapeutics, Inc.¹⁰
• Aug 17, 2026Sold 1,900 shares at $62.53 of Travere Therapeutics, Inc.¹⁰
• Aug 17, 2026Exercised options 5,000 shares at $17.44 of Travere Therapeutics, Inc.¹⁰
• May 21, 2026Exercised options 1,659 shares of Neurocrine Biosciences⁸
• May 19, 2026Granted 4,000 shares of Travere Therapeutics, Inc.¹¹
• Apr 14, 2026Sold 8,000 shares at $41.07 of Travere Therapeutics, Inc.¹²
• Apr 14, 2026Exercised options 8,000 shares at $16.33 of Travere Therapeutics, Inc.¹²
• Dec 3, 2025Sold 15,000 shares at $152.61 of Neurocrine Biosciences¹³
• Dec 3, 2025Exercised options 15,000 shares at $47.89 of Neurocrine Biosciences¹³
• May 22, 2025Exercised options 1,435 shares of Neurocrine Biosciences¹⁴
• May 15, 2025Granted 6,500 shares of Travere Therapeutics, Inc.¹⁵
• Oct 4, 2024Sold 18,821 shares at $15.15 of Travere Therapeutics, Inc.¹⁶
• Oct 4, 2024Sold 21,179 shares at $14.35 of Travere Therapeutics, Inc.¹⁶
• Oct 4, 2024Exercised options 40,000 shares at $10.48 of Travere Therapeutics, Inc.¹⁶
• Aug 13, 2024Sold 11,570 shares at $150.43 of Neurocrine Biosciences¹⁷
• Aug 13, 2024Exercised options 11,570 shares at $42.76 of Neurocrine Biosciences¹⁷
• Jul 16, 2024Sold 930 shares at $150.03 of Neurocrine Biosciences¹⁸
• Jul 16, 2024Exercised options 930 shares at $42.76 of Neurocrine Biosciences¹⁸
• May 17, 2024Exercised options 2,100 shares of Neurocrine Biosciences¹⁹
• May 14, 2024Sold 12,500 shares at $135.63 of Neurocrine Biosciences²⁰
• May 14, 2024Exercised options 12,500 shares at $42.76 of Neurocrine Biosciences²⁰